Yahoo · Sep 16, 2026
Should You Buy PMV Pharmaceuticals, Inc. (PMVP) After Golden Cross?
When a stock experiences a golden cross technical event, good things could be on the horizon. How should investors react?
PM
NASDAQ · PMVP
PMV Pharmaceuticals, Inc.
Healthcare · Biotechnology
$1.50
Down-$0.11 (-6.83%)
Updated Oct 8, 2026, 5:13 AM
SID Score
4.2/10
Composite research score
Smart Money
—
Institutional and insider signal
- Market cap
- 66.78M
- P/E ratio
- -0.81
- Dividend yield
- 0.00%
- 52-week range
- $1.04 – $1.91
- Volume
- 607.44K
- Avg. volume
- 564.7K
Price performance · PMVP
PMVP price history
1M range · 21 trading sessions · Daily adjusted prices
Prices through Oct 7, 2026
PMVP closed at $1.50 after 21 trading sessions, up 9.09% for the selected period.
- Last close
- $1.50
- Period change
- +9.09%
- Period low
- $1.33
- Period high
- $1.79
Daily close
View OHLC price history
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Oct 7, 2026 | $1.59 | $1.60 | $1.48 | $1.50 | 607.44K |
| Oct 6, 2026 | $1.78 | $1.81 | $1.5908 | $1.61 | 616.11K |
| Oct 5, 2026 | $1.80 | $1.84 | $1.70 | $1.78 | 1.19M |
| Oct 2, 2026 | $1.75 | $1.87 | $1.68 | $1.79 | 3.74M |
| Oct 1, 2026 | $1.68 | $1.91 | $1.63 | $1.75 | 1.65M |
| Sep 30, 2026 | $1.44 | $1.725 | $1.44 | $1.67 | 3.13M |
| Sep 29, 2026 | $1.37 | $1.45 | $1.36 | $1.43 | 550.86K |
| Sep 28, 2026 | $1.34 | $1.39 | $1.30 | $1.36 | 341.56K |
| Sep 25, 2026 | $1.32 | $1.38 | $1.29 | $1.33 | 271.15K |
| Sep 24, 2026 | $1.36 | $1.40 | $1.28 | $1.335 | 486.35K |
| Sep 23, 2026 | $1.51 | $1.52 | $1.365 | $1.37 | 574.28K |
| Sep 22, 2026 | $1.47 | $1.525 | $1.46 | $1.51 | 316.92K |
| Sep 21, 2026 | $1.50 | $1.51 | $1.445 | $1.475 | 329.96K |
| Sep 18, 2026 | $1.46 | $1.52 | $1.43 | $1.50 | 1.18M |
| Sep 17, 2026 | $1.43 | $1.50 | $1.42 | $1.46 | 430.8K |
| Sep 16, 2026 | $1.37 | $1.51 | $1.37 | $1.43 | 1.02M |
| Sep 15, 2026 | $1.45 | $1.45 | $1.35 | $1.36 | 705.95K |
| Sep 14, 2026 | $1.42 | $1.495 | $1.38 | $1.46 | 1.11M |
| Sep 11, 2026 | $1.45 | $1.505 | $1.40 | $1.40 | 539.35K |
| Sep 10, 2026 | $1.34 | $1.45 | $1.34 | $1.44 | 673.56K |
| Sep 9, 2026 | $1.34 | $1.39 | $1.34 | $1.375 | 420.1K |
Latest PMVP news
The latest Smart Investors Daily articles mentioning PMVP.
Stock researchCompany · Overview
Company
Market Activity
Research & News
PMVP research
Overview
Company profile and research snapshot.
Company profile
PMV Pharmaceuticals Inc is a precision oncology company. The company is engaged in the research and development of small molecule, tumor-agnostic therapies targeting p53 mutations, which can eliminate cancer cells. Its pipeline rezatapopt PYNNACLE, rezatapopt and azacitidine, rezatapopt (PC14586), and PMV-586-101.
Visit company websiteAnalyst outlook
Consensus and target data currently published for this company.
- Consensus
- —
- Average target
- $18.00
- Implied upside
- —
- Analysts
- —
| Date | Firm | Rating | Target |
|---|---|---|---|
| Sep 4, 2026 | HC Wainwright & Co. | Buy | — |
| May 13, 2026 | Oppenheimer | Outperform | — |
| Mar 20, 2025 | HC Wainwright & Co. | Buy | — |
| Aug 20, 2024 | HC Wainwright & Co. | Buy | — |
| May 30, 2024 | HC Wainwright & Co. | Buy | — |
News briefing
No generated briefing is available yet.
Yahoo · Sep 8, 2026
PMV Pharmaceuticals Appoints Philip Herman as Chief Commercial Officer
Commercial leadership appointment supports launch preparation for rezatapopt Company planning NDA submission for accelerated approval of rezatapopt in patients with platinum-resistant/refractory ovarian cancer in first quarter of 2027 PRINCETON, N.J., Sept. 08, 2026 (GLOBE NEWSWIRE) -- PMV Pharmaceuticals, Inc. (“PMV Pharma” or the “Company”; Nasdaq: PMVP), a precision oncology company pioneering the discovery and development of small molecule therapies targeting p53, today announced the appoint
Yahoo · Sep 1, 2026
PMV Pharma Raises $50.8 Million to Fuel Cancer Drug Push
PMV Pharmaceuticals Inc. (NASDAQ:PMVP) on Monday shared interim data from its Phase 2 PYNNACLE trial for rezatapopt, an investigational treatment for ovarian cancer.Based on this data, the company announced its plans to submit a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for accelerated approval of the drug.Efficacy HighlightsThe interim data, gathered up to May 14, 2026, focus on patients with platinum-resistant or refractory ovarian cancer bearing the TP53 Y220C
Benzinga · Sep 1, 2026
PMV Pharma Raises $50.8 Million to Fuel Cancer Drug Push
PMV Pharmaceuticals reports 46% ORR in Phase 2 trial for ovarian cancer drug rezatapopt. NDA submission planned for Q1 2027.
AI research layers
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
